Project Details
Description
This clinical trial adopts a randomized, double-blind and placebo-controlled design.
A total of 16000 participants are planned to be enrolled, of which, Cohort 1: 15000 participants vaccinated with ≥2 doses of inactivated COVID-19 vaccine for ≥6 months will be randomly administered at ratio of 1:1:1 with 1 dose of LIBP-Rec-Vaccine, BIBP-Rec-Vaccine or placebo intramuscularly to the deltoid muscle of upper arm.
Cohort 2: 1000 participants vaccinated with ≥2 doses of mRNA COVID-19 vaccine for ≥6 months will be randomly administered at ratio of 1:1 with 1 dose of LIBP-Rec-Vaccine or BIBP-Rec-Vaccine intramuscularly to the deltoid muscle of upper arm.
A total of 16000 participants are planned to be enrolled, of which, Cohort 1: 15000 participants vaccinated with ≥2 doses of inactivated COVID-19 vaccine for ≥6 months will be randomly administered at ratio of 1:1:1 with 1 dose of LIBP-Rec-Vaccine, BIBP-Rec-Vaccine or placebo intramuscularly to the deltoid muscle of upper arm.
Cohort 2: 1000 participants vaccinated with ≥2 doses of mRNA COVID-19 vaccine for ≥6 months will be randomly administered at ratio of 1:1 with 1 dose of LIBP-Rec-Vaccine or BIBP-Rec-Vaccine intramuscularly to the deltoid muscle of upper arm.
| Status | Finished |
|---|---|
| Effective start/end date | 4/11/22 → 31/12/23 |
Collaborative partners
- National Vaccine and Serum Institute, China (lead)
- China National Biotec Group Company Limited
- Lanzhou Institute of Biological Products Co., Ltd.
- Beijing Institute of Biological Products Co., Ltd.
- Sheikh Khalifa Medical City
Keywords
- Pneumonia, Viral
- Pneumonia
- Respiratory Tract Infections
- Infections
- Virus Diseases
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Lung Diseases
- Respiratory Tract Diseases
- COVID-19
- Coronavirus Infections
- Immunologic Factors
- Physiological Effects of Drugs
- Vaccines
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.